The Advisory Council on the Misuse of Drugs (ACMD) has published
a report reviewing the availability and use of naloxone in the
UK, a drug used to reverse opioid overdose.
The advice follows a self-commission by ACMD members in 2019
after a small rise in opioid overdose-related deaths.
The report outlines evidence that administration of naloxone
leads to a reduction in these types of deaths, however it also
concluded that more work is needed to increase the availability
and use of this drug.
The report has made the following recommendations to government:
-
Improve the quality of data on take-home naloxone and ensure
local authority commissioners monitor how it is provided by
service providers.
-
Further research should be undertaken to see how those at
risk of overdose can more easily access take-home naloxone.
-
Good examples of partnership working cited in the report
should be used to model naloxone programmes across the UK.
-
Prison services should ensure people being released from
prison who are at high-risk of overdosing have access to
take-home naloxone.
-
Additional training for police in the holding and
administration of naloxone should be provided and police
services should register to gain required exemptions to
supply take-home naloxone.
-
Hospitals, mental health trusts and ambulance services should
deliver take-home naloxone and training to those at risk of
overdose. Guidance should be updated to include appropriate
recommendations on naloxone provision.
-
There should be arrangements across the UK which allow
community pharmacies to deliver take-home naloxone and
intervention on managing opioid overdoses.
The ACMD has previously reviewed the use and availability of
naloxone in 2012 and recommended it to be made more widely
available.
In 2015 the government introduced changes to the Human Medicines
Amendment Regulations (2012) which expanded the availability of
naloxone in the UK, but this report hopes to encourage a further
increase in naloxone availability and use.
ACMD chair Professor Owen Bowden-Jones said:
We are pleased to share today our findings on take-home naloxone.
Naloxone is a life-saving medication and it is crucial that it is
easily available to people at risk. Only a national, cross-sector
approach will achieve this.
We look forward to the Government response to this report and our
findings.
Read the ACMD naloxone review.
